IFNB1 and melanoma: Moreover, assessment of the antitumor effects of combination therapy with the canine AT-MSCs producing IFN-β and cisplatin in B16F10 melanoma-bearing mice evidenced that intratumoral administration of cisplatin along with subcutaneous injection of modified AT-MSCs was superior in terms of abrogation of the melanoma tumor growth and survival, over the administration of modified AT-MSCs or cisplatin alone (Seo K.W. et al., 2011).